Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Luis Javier, Lin, Leyi, Blaylock, Jason M., Lyons, Arthur G., Bauer, Kristen M., De La Barrera, Rafael, Simmons, Monika, Jarman, Richard G., Currier, Jeffrey R., Friberg, Heather, Danko, Janine R., Teneza-Mora, Nimfa C., Putnak, J. Robert, Eckels, Kenneth H., Thomas, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559679/
https://www.ncbi.nlm.nih.gov/pubmed/26149862
http://dx.doi.org/10.4269/ajtmh.14-0819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559679/
https://www.ncbi.nlm.nih.gov/pubmed/26149862
http://dx.doi.org/10.4269/ajtmh.14-0819

Ejemplares similares